Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 3:9:5897-909.
doi: 10.2147/DDDT.S70432. eCollection 2015.

Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis

Alessandra Scaparrotta  1 , Marina Attanasi  1 , Marianna I Petrosino  1 , Paola Di Filippo  1 , Sabrina Di Pillo  1 , Francesco Chiarelli  1
Affiliations
Review

Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis

Alessandra Scaparrotta et al. Drug Des Devel Ther. .

Abstract

Allergic rhinitis is one of the most common diseases of adult and pediatric age, associated with grass pollen (GP) allergy in >50% cases, with a consistent impact on quality of life of affected patients. A grass allergen tablet, containing standardized extract derived from Timothy grass (Phleum pratense) pollen and ~15 μg major allergen P. pratense (rPhl p 5), may be the future of allergen-specific immunotherapy (IT) for GP allergy. The aim of this review was to critically evaluate the role of Timothy GP extract IT for the management of allergic rhinitis. For this purpose, we have tried to analyze potential mechanisms of action at the basis of Timothy GP extract, we have reviewed efficacy studies to establish potential benefits and clinical response, and we have also evaluated safety and tolerability profiles and patient focus perspective, such as quality of life, satisfaction and acceptability, and compliance to this IT.

Keywords: Grazax; Timothy grass pollen extract; allergic rhinitis; compliance; efficacy; safety.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725. - PubMed
    1. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197–206. - PubMed
    1. Calderón M, Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax®. Ther Clin Risk Manag. 2008;4(6):1255–1260. - PMC - PubMed
    1. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007;62(8):954–957. - PubMed
    1. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61(2):185–190. - PubMed